Literature DB >> 21352916

Formulation of zolmitriptan sublingual tablets prepared by direct compression with different polymers: in vitro and in vivo evaluation.

Ziya Bayrak1, Cetin Tas, Umut Tasdemir, Halil Erol, Cansel Kose Ozkan, Ayhan Savaser, Yalcin Ozkan.   

Abstract

First-pass metabolism can be overcome by sublingual drug delivery, and quick drug entry into the systemic circulation can be obtained. In certain diseases such as migraine therapy, taking fast pharmacological response is an important criteria. In this study, zolmitriptan sublingual tablets were prepared by direct compression method using different mucoadhesive polymers such as hydroxypropyl methyl cellulose, chitosan and sodium carboxy methyl cellulose at a concentration range of 0.5-5% to reduce flushing action of saliva and provide enough time for drug to be absorbed. Tablets were evaluated for the physical properties, and optimum formulations were chosen for in vivo studies to carry on sheep model. The tablets disintegrated rapidly, and dissolution tests revealed that zolmitriptan was dissolved from the formulation within the compendial limits. This especially showed us that the concentration range of polymers is in acceptable limit. It was also concluded that microcrystalline cellulose, spray-dried lactose and sodium starch glycolate are the appropriate excipient and formulated in good proportions. In vivo studies indicated that formulation containing 5% chitosan has the maximum C(max) and AUC and minimum t(max) values (p<0.05). As a result, sublingual tablet administration of zolmitriptan formulated with appropriate excipients and especially with chitosan seems promising alternative to traditional routes.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21352916     DOI: 10.1016/j.ejpb.2011.02.014

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  8 in total

1.  Engineering of a novel optimized platform for sublingual delivery with novel characterization tools: in vitro evaluation and in vivo pharmacokinetics study in human.

Authors:  Nadia M Morsi; Ghada A Abdelbary; Ahmed H Elshafeey; M Abdallah Ahmed
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

2.  Preparation and evaluation of sublingual tablets of zolmitriptan.

Authors:  Shailesh T Prajapati; Manoj V Patel; Chhaganbhai N Patel
Journal:  Int J Pharm Investig       Date:  2014-01

3.  Sublingual Delivery of Frovatriptan: An Indication of Potential Alternative Route.

Authors:  Hitesh Verma; Surajpal Verma; Shyam Baboo Prasad; Harmanpreet Singh
Journal:  Int Sch Res Notices       Date:  2014-10-29

4.  Exploitation of Design-of-Experiment Approach for Design and Optimization of Fast-Disintegrating Tablets for Sublingual Delivery of Sildenafil Citrate with Enhanced Bioavailability Using Fluid-Bed Granulation Technique.

Authors:  Amer S AlAli; Mohammed F Aldawsari; Ahmed Alalaiwe; Bjad K Almutairy; Ramadan Al-Shdefat; Ismail A Walbi; Mohamed H Fayed
Journal:  Pharmaceutics       Date:  2021-06-12       Impact factor: 6.321

5.  Scalable flibanserin nanocrystal-based novel sublingual platform for female hypoactive sexual desire disorder: engineering, optimization adopting the desirability function approach and in vivo pharmacokinetic study.

Authors:  Marianne J Naguib; Amal I A Makhlouf
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

6.  Formulation and evaluation of sublingual tablets containing Sumatriptan succinate.

Authors:  Shailesh T Prajapati; Parth B Patel; Chhagan N Patel
Journal:  Int J Pharm Investig       Date:  2012-07

7.  Development and evaluation of fixed dose bi therapy sublingual tablets for treatment stress hypertension and anxiety.

Authors:  Mohamed A El-Nabarawi; Saadia A Tayel; Nadia A Soliman; Hadel A Abo Enin
Journal:  J Pharm Bioallied Sci       Date:  2013-07

8.  Effect of polymer type on characteristics of buccal tablets using factorial design.

Authors:  O Esim; A Savaser; C K Ozkan; Z Bayrak; C Tas; Y Ozkan
Journal:  Saudi Pharm J       Date:  2017-10-26       Impact factor: 4.330

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.